Table of Content

1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Demand From Governments For Diagnosing Covid-19 Positive Patients
3.2.2. Rise In Demand For Non-Invasive Diagnosis
3.2.3. Growth In The Number Of Diseases
3.2.4. Funding For Research And Development
3.2.5. Technological Advancements In The Market
3.3. Key Restraints
3.3.1. High Capital Requirement
3.3.2. Lack Of High Complexity Testing Centers

4. Key Analytics
4.1. Key Investment Insights
4.2. Porter’S Five Force Analysis
4.2.1. Buyer Power
4.2.2. Supplier Power
4.2.3. Substitution
4.2.4. New Entrants
4.2.5. Industry Rivalry
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Regulatory Framework

5. Market By Technology
5.1. Polymerase Chain Reaction
5.1.1. Real Time Pcr
5.1.2. Digital Pcr
5.2. Isothermal Nucleic Acid Amplification Technology
5.3. Other

6. Market By Product
6.1. Assays
6.2. Instruments
6.3. Software

7. Market By Application
7.1. Infectious Disease
7.1.1. Respiratory
7.1.2. Hospital Acquired Infections
7.1.3. Sexually Transmitted Infections
7.1.4. Gastro Intestinal Infections
7.2. Oncology
7.3. Prenatal
7.4. Others

8. Market By End-User
8.1. Hospitals
8.2. Clinics
8.3. Diagnostics Centres
8.4. Others

9. Geographical Analysis
9.1. Asia Pacific
9.1.1. China
9.1.2. Japan
9.1.3. India
9.1.4. South Korea
9.1.5. Indonesia
9.1.6. Thailand
9.1.7. Vietnam
9.1.8. Australia & New Zealand
9.1.9. Rest Of Asia Pacific

10. Company Profiles
10.1. Abbott Laboratories
10.2. Abacus Diagnostica
10.3. Biom?rieux Sa
10.4. Biocartis Nv
10.5. Danaher Corporation
10.6. Diasorin Spa
10.7. Bio-Rad
10.8. F Hoffmann-La Roche Ag
10.9. Luminex Corporation
10.10. Hologic Inc
10.11. Mesa Biotech
10.12. Spartan Biosciences Inc
10.13. Quantumdx Group Ltd
10.14. Quidel Corporation
10.15. Qiagen Nv



List of Figures


Figure 1: Key Investment Insights
Figure 2: Porter’S Five Force Analysis
Figure 3: Value Proposition - Laboratory, Immunoassay, And Molecular Poc Diagnostic
Figure 4: Opportunity Matrix
Figure 5: Vendor Landscape
Figure 6: Asia Pacific Molecular Point Of Care Diagnostics Market, Growth Potential, By Technology, In 2018
Figure 7: Asia Pacific Molecular Point Of Care Diagnostics Market, By Polymerase Chain Reaction, 2019-2028 (In $ Million)
Figure 8: Asia Pacific Molecular Point Of Care Diagnostics Market, Growth Potential, By Pcr Technology, In 2018
Figure 9: Asia Pacific Molecular Point Of Care Diagnostics Market, By Real Time Pcr, 2019-2028 (In $ Million)
Figure 10: Asia Pacific Molecular Point Of Care Diagnostics Market, By Digital Pcr, 2019-2028 (In $ Million)
Figure 11: Asia Pacific Molecular Point Of Care Diagnostics Market, By Isothermal Nucleic Acid Amplification Technology, 2019-2028 (In $ Million)
Figure 12: Asia Pacific Molecular Point Of Care Diagnostics Market, By Other, 2019-2028 (In $ Million)
Figure 13: Asia Pacific Molecular Point Of Care Diagnostics Market, Growth Potential, By Product, In 2018
Figure 14: Asia Pacific Molecular Point Of Care Diagnostics Market, By Assays, 2019-2028 (In $ Million)
Figure 15: Asia Pacific Molecular Point Of Care Diagnostics Market, By Instruments, 2019-2028 (In $ Million)
Figure 16: Asia Pacific Molecular Point Of Care Diagnostics Market, By Software, 2019-2028 (In $ Million)
Figure 17: Asia Pacific Molecular Point Of Care Diagnostics Market, Growth Potential, By Application, In 2018
Figure 18: Asia Pacific Molecular Point Of Care Diagnostics Market, By Infectious Disease, 2019-2028 (In $ Million)
Figure 19: Asia Pacific Molecular Point Of Care Diagnostics Market, Growth Potential, By Infectious Disease, In 2018
Figure 20: Asia Pacific Molecular Point Of Care Diagnostics Market, By Respiratory, 2019-2028 (In $ Million)
Figure 21: Asia Pacific Molecular Point Of Care Diagnostics Market, By Hospital Acquired Infections, 2019-2028 (In $ Million)
Figure 22: Asia Pacific Molecular Point Of Care Diagnostics Market, By Sexually Transmitted Infections, 2019-2028 (In $ Million)
Figure 23: Asia Pacific Molecular Point Of Care Diagnostics Market, By Gastro Intestinal Infections, 2019-2028 (In $ Million)
Figure 24: Asia Pacific Molecular Point Of Care Diagnostics Market, By Oncology, 2019-2028 (In $ Million)
Figure 25: Asia Pacific Molecular Point Of Care Diagnostics Market, By Prenatal, 2019-2028 (In $ Million)
Figure 26: Asia Pacific Molecular Point Of Care Diagnostics Market, By Others, 2019-2028 (In $ Million)
Figure 27: Asia Pacific Molecular Point Of Care Diagnostics Market, Growth Potential, By End-User, In 2018
Figure 28: Asia Pacific Molecular Point Of Care Diagnostics Market, By Hospitals, 2019-2028 (In $ Million)
Figure 29: Asia Pacific Molecular Point Of Care Diagnostics Market, By Clinics, 2019-2028 (In $ Million)
Figure 30: Asia Pacific Molecular Point Of Care Diagnostics Market, By Diagnostic Centres, 2019-2028 (In $ Million)
Figure 31: Asia Pacific Molecular Point Of Care Diagnostics Market, By Others, 2019-2028 (In $ Million)
Figure 32: Asia Pacific Molecular Point Of Care Diagnostics Market, Regional Outlook, 2019 & 2028 (In %)
Figure 33: China Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 34: Japan Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 35: India Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 36: South Korea Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 37: Indonesia Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 38: Thailand Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 39: Vietnam Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 40: Australia & New Zealand Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 41: Rest Of Asia Pacific Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)


List of Tables


TABLE 1: MARKET SNAPSHOT - MOLECULAR POINT OF CARE DIAGNOSTICS
TABLE 2: EMERGENCY USE AUTHORISATION FOR DIAGNOSTICS BY FDA
TABLE 3: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 5: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 7: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 8: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 9: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 10: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 11: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 12: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 13: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 14: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 15: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 16: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)